Compare Mesoblast Limited (MESO) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Synopsys, Inc. — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Synopsys, Inc. trades at $502 (market cap $96.33B). The key difference: Synopsys, Inc. is far larger — about 53.2× Mesoblast Limited's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Synopsys, Inc. for 71 Days on average.
| MESO | SNPS | |
|---|---|---|
Market Cap | $1.81B | $96.33B |
Volume | 240,620 | 1,631,837 |
Sector | Health | Technology |
52-Week High | $20.96 | $534.56 |
52-Week Low | $13.19 | $367.70 |
Typical Hold Time | 14 Days | 71 Days |
Enterprise Value | $1.89B | $103.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Synopsys (SNPS) trades at $497.75, down 1.47% on the day but remains near recent highs following strong quarterly earnings beats and bullish investor sentiment driven by AI partnerships. The stock shows a bullish technical trend with moving averages supporting upside, while RSI levels indicate overbought conditions. Recent news highlights multi-year agreements with OpenAI and Amazon Web Services, fueling growth expectations beyond traditional EDA markets.
The outlook is positive with a consensus price target of $572.54, reflecting 15% upside potential, though high valuation multiples (P/E of 87.73) and integration risks from the Ansys acquisition warrant caution. Revenue growth is projected to accelerate, supported by AI-driven demand, but margin compression and competitive pressures pose medium-term risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
